NEW YORK, Sept. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=104019&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

There's no hope of it recovering to its prior heights anytime soon. Moderna's (MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is cautioning investors that a return to routine profitability may not be in the cards for a couple of years. Is the stock's decline just a blip that's part and parcel with the announcement of less-than-great news, or is there a real risk of a long ...

In my previous article , I argued that Moderna stock was undervalued. Since then, Moderna's stock has rallied to $170 per share (May 24), surpassing my fair valuation level of $157. However, the stock has since suffered a sell-off, and after the R&D day, the stock price was as I am the head of research for the pre-IPO and venture division of the investment bank. Prior to that, I have been working as a global equity research analyst in an investment bank for the past 5 years. My specialization are Biotechnol ...

This strategic play will take time to pay off, but it could keep growth going. On Sept. 16 Novo Nordisk (NVO 0.04%) and Korro Bio (KRRO -1.45%) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most would assume to be Moderna's (MRNA -2.96%) home territory. It's natural for investors to wonder if the competitive landscape in biopharma may have changed in a big way. And it might -- but probably not in the way that some are expecting. ...

NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=103493&from=4 CLASS PERIOD: January 18, 2023 to June 2 ...

SAN DIEGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular dis ...

NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=103175&from=3 CLASS PERIOD: January 18, 2023 to Ju ...

Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm's updated COVID-19 vaccine. Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA) shares surged Tuesday after Canadian regulators approved the biotech firm's updated COVID-19 vaccine. The company reported Health Canada authorized the use of its Spikevax KP.2 shot for thos ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Moderna To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Moderna between January 18, 2023 and June 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 17, 2024 /PRNews ...

Moderna (MRNA) closed the most recent trading day at $69.17, moving +1.3% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.13%. On the other hand, the Dow registered a gain of 0.55%, and the technology-centric Nasdaq decreased by 0.52%. Heading into today, shares of the biotechnology company had lost 21.37% over the past month, lagging the Medical sector's gain of 3.34% and the S&P 500's gain of 3.67% in that time. Market participants will be closely following the financia ...